- ￥1070 - 5390
- Solarbio
- 北京
- IA7440
- 2025年10月10日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
AV-412 free base
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
451492-95-8
- 规格：
50mg/10mg/5mg
| 规格： | 50mg | 产品价格： | ￥5390.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥1790.0 |
| 规格： | 5mg | 产品价格： | ￥1070.0 |
| 基本信息 | |
| CAS | No.451492-95-8 |
| 英文名称 | AV-412 free base |
| 别名 | MP-412 free base |
| 分子式 | C27H28ClFN6O |
| 分子量 | 507 |
| 溶解性 | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | White to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD16038939 |
| SMILES | CC(C)(C#CC1=CC2=C(C=C1NC(=O)C=C)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)N4CCN(CC4)C |
| InChIKey | ZAJXXUDARPGGOC-UHFFFAOYSA-N |
| InChI | InChI=1S/C27H28ClFN6O/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2，3)35-12-10-34(4)11-13-35/h5-7，14-17H，1，10-13H2，2-4H3，(H，33，36)(H，30，31，32) |
| PubChem CID | 9806229 |
| 靶点 | EGFR |
| 通路 | Angiogenesis;Protein Tyrosine Kinase/RTK |
| 背景说明 | AV-412 free base是 EGFR 抑制剂。 |
| 生物活性 | AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75， 0.5， 0.79， 2.3， 19 nM for EGFR， EGFRL858R， EGFRT790M， EGFRL858R/T790M and ErbB2， respectively.[1] |
| In Vitro | AV-412 inhibits autophosphorylation of EGFR and ErbB2 with IC50 of 43 and 282 nM， respectively. AV-412 also inhibits epidermal growth factor (EGF)-dependent cell proliferation with an IC50 of 100 nM. AV-412 abrogates EGFR signaling in the gefitinib-resistant H1975 cell line， which harbors a double mutation of L858R and T790M in EGFR[1]. |
| 细胞实验 | In animal studies using cancer xenograft models， AV-412 (30 mg/kg) demonstrates complete inhibition of tumor growth of the A431 and BT-474 cell lines， which overexpress EGFR and ErbB2， respectively. AV-412 suppresses autophosphorylation of EGFR and ErbB2 at the dose corresponding to its antitumor efficacy. When various dosing schedules are applied， AV-412 shows significant effects with daily and every-other-day schedules， but not with a once-weekly schedule， suggesting that frequent dosing is preferable for this compound. Furthermore， AV-412 shows a significant antitumor effect on the ErbB2-overexpressing breast cancer KPL-4 cell line， which is resistant to gefitinib[1]. |
| 细胞实验 | To test the effects of AV-412 on growth factor-dependent cell proliferation， A431 and A7r5 cells are cultured for 24 h at 37°C in the presence of 1 ng/mL epidermal growth factor and 50 ng/mL platelet-derived growth factor， respectively. The 3H-thymidine incorporation during this period is measured[1]. |
| 动物实验 | Mice: For studies examining the dosing schedule in relation to efficacy against TE-8 tumors， AV-412 is administered either once daily， every other day， or once per week for 2 weeks. Mice are killed 1 day after the final treatment， and the tumors are dissected and weighed. For evaluation of tumor phosphorylation， tumor-bearing mice are given a single administration of AV-412 and tumors are dissected 4 h later[1]. |
| 激酶实验 | Recombinant intracellular kinase domains of EGFR， EGFRL858R， EGFRT790M， EGFRL858R/T790M， and purified EGFR from A431 cell membranes are used. Kinase reactions are carried out in 8 mM MOPS (pH 7.0)， 0.2 mM ethylenediaminetetraacetic acid (EDTA)， 10 mM MnCl2， 10 mM Mg acetate， 0.1 mg/mL poly(Glu， Tyr) 4:1， [γ33P-ATP]， and 5–10 mU of enzyme， except that 250 μM of the GGMEDIYFEFMGGKKK peptide substrate is used for EGFRT790M. Phosphorylation is initiated by the addition of ATP and is allowed to proceed for 40 min at room temperature. The reaction is stopped by the addition of 3% phosphoric acid， then aliquots of the reaction mixture are spotted onto a filtermat. After rinsing to remove peptides bound non-specifically， the filter is scintillation counted[1]. |
| 数据来源文献 | [1]. Suzuki T， et al. Pharmacological characterization of MP-412 (AV-412)， a dual epidermal growth factor receptorand ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007 Dec;98(12):1977-84. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验reporter plasmids (TCF reporter plasmid kit; Upstate) is needed. B Pharmacological inhibition ofGSK-3 activity. MiaPaCa2 pancreatic cancer cells do not express E-cadherin and there is free (free from binding to Ecadherin)cytosolic β-catenin pool
Avoiding DNA Contamination in RT-PCR
. Primer Design Primers for quantitative experiments are typically designed to amplify a target between 150 and 600 base pairs. Targets smaller than 200 bp are difficult to resolve on agarose gels, and larger targets
by partial pairing between the CRISPRRNA (crRNA), which includes the guide sequence that bound totarget DNA through Watson–Crick base-pairing to specify the siteof cleavage, and the trans-activating crRNA (tracrRNA), whichfacilitate the maturation of crRNA
技术资料暂无技术资料 索取技术资料
